UWM
MRNA icon

Urban Wealth Management’s Moderna MRNA Stock Holding History

Urban Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$18K Buy
+124
New +$17.7K 0.06% 155

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Urban Wealth Management's MRNA Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Moderna (MRNA) in Q2 2022: 124 shares worth $18K. The stake represents 0.06% of the portfolio and ranks #155 among its holdings.

981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • Urban Wealth Management held 124 shares of Moderna worth $18K as of Q2 2022.
  • Moderna was a new Urban Wealth Management position in Q2 2022.
  • Moderna made up 0.06% of Urban Wealth Management's portfolio in Q2 2022, its #155 holding.
  • 981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.